Maria Babak: Vimseltinib in treating TGCT is definitely one to watch
Maria Babak shared a post on LinkedIn by The Babak Lab, about a recent paper by Hans Gelderblom et al. published in Clinical Cancer Research.
Authors: Hans Gelderblom, Albiruni Razak, Rodrigo Ruiz-Soto, Matthew Sherman, William Tap et al.
“Vimseltinib in treating TGCT is definitely one to watch! With a 72% response rate and a well-tolerated safety profile, it offers new hope for patients who aren’t candidates for surgery. It’s exciting to see targeted therapies making such an impact in oncology”
Quoting
“Exciting Advances in Cancer Treatment!
A recent clinical trial of vimseltinib, a new tyrosine kinase inhibitor, has shown promising results in treating tenosynovial giant cell tumor (TGCT) – particularly in patients where surgery isn’t an option.
Key Results:
- 72% response rate in patients with TGCT.
- Well-tolerated with manageable side effects.
- Long-lasting responses, with patients on treatment for over 2 years.
- With limited options for those not eligible for surgery, vimseltinib represents a breakthrough in TGCT treatment.
More research is on the horizon, but these findings highlight the potential for targeted therapies in oncology!”
Sources: Maria Babak/LinkedIn and
More posts featuring Maria Babak on oncodaily.com
Maria (Masha) Babak is the Head of The Babak Lab and an Assistant Professor at the City University of Hong Kong. In November 2020, she joined the City University of Hong Kong as an assistant professor. Dr. Babak received the Graeme Hanson-AsBIC Early Career Award in 2022.
Her research interests are at the intersection of chemistry, biology, and medicine, with a focus on the discovery and preclinical development of anticancer drugs for resistant and aggressive cancers with limited treatment options, such as malignant pleural mesothelioma and brain metastases.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023